Crinetics Pharmaceuticals Inc (NAS:CRNX)
$ 57.67 0.9 (1.59%) Market Cap: 5.35 Bil Enterprise Value: 4.54 Bil PE Ratio: 0 PB Ratio: 5.60 GF Score: 39/100

Crinetics Pharmaceuticals Inc Review CRN04894 Single Ascending Dose Results Call Transcript

Aug 10, 2021 / 08:30PM GMT
Release Date Price: $17.6 (+4.27%)
Operator

Greetings, and welcome to the Crinetics Pharmaceuticals Conference Call. (Operator Instructions) As a reminder, this conference is being recorded Tuesday, August 10, 2021. I would now like to turn the conference over to Corey Davis, LifeSci Advisers. Please go ahead.

Corey George Davis
LifeSci Advisors, LLC - Relationship Manager

Thank you, operator, and thanks to everyone for participating in today's call. Before we start, I'd like to point out there is a slide deck that's going to accompany today's presentation. The deck can be viewed using the webcast link that's on the IR section of the Crinetics website, and you can download a copy of the slide deck as well.

Also posted on that same IR website is a news release issued earlier today, announcing data from the Phase I single ascending dose study evaluating CRN04894. A press release announcing the company's financial results for the quarter ended June 30, 2021, is also available on the company's website, though that is not the focus of today's call.

Before handing it off to Crinetics to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot